Zeltia S.A.: Report at 30 June 2006

Madrid, Spain (ots/PRNewswire) - Corporate:

- Zeltia performs 1-for-50 bonus issue

- Group revenues amounted to 42.5 million euro.

- Investment in R&D amounted to 24.4 million euro in the first half of 2006.

- The net cash position (cash + cash equivalents + current financial assets - short-term borrowings) amounted to 55.3 million euro.

PharmaMar:

- Excellent results of Yondelis in myxoid liposarcomas and ovarian carcinoma presented at ASCO 2006

NeuroPharma:

- Progress with its first clinical-phase compound

Zelnova:

- Entered the Italian market by acquiring Copyr

Isabel Lozano Catherine Moukheibir M(a) Luisa de Francia Chief Executive Head of Capital Chief Financial Officer Officer Market Strategy
ZELTIA, S.A.
PHARMAMAR, S.A. ZELTIA, S.A.
José Abascal, 2. Madrid C/ Reyes, 1. José Abascal, 2.
Colmenar Viejo Madrid Telephone +34-91-444-45-00 Madrid Telephone
+34-91-444-45-00
Telephone
+34-91-846-60-00

For a copy of the full results, please refer to www.zeltia.com

Rückfragen & Kontakt:

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/Reyes, 1.
Colmenar Viejo, Madrid, Telephone +34-91-846-60-00, Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00, M(a) Luisa de
Francia, Chief Financial Officer, ZELTIA, S.A., José Abascal, 2.
Madrid, Telephone +34-91-444-45-00

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | PRN0006